Atopic Dermatitis
5 videos · updated daily
8:36 Mahalo Recruit: AI Patient Recruitment Demo
Mahalo Health founder and CEO Prasanna Gopinath demonstrates Mahalo Recruit, an AI patient recruitment platform that reads eligibility criteria and screens site health records, using the public ADvocate1 atopic dermatitis protocol and synthetic data.
6:38 Lebrikizumab in Atopic Dermatitis: 52-Week Phase III Results
The British Journal of Dermatology presents an author video on 52-week efficacy and safety results of two randomised, double-blinded, placebo-controlled phase III trials of lebrikizumab in moderate-to-severe atopic dermatitis.
5:21 Tralokinumab in Atopic Dermatitis: ECZTRA 1 and 2 Results
The British Journal of Dermatology presents an author video on 52-week results from ECZTRA 1 and ECZTRA 2, two randomised, double-blind, placebo-controlled phase III trials of tralokinumab in moderate-to-severe atopic dermatitis.
5:02 Amlitelimab in Atopic Dermatitis: Phase IIa Trial Results
The British Journal of Dermatology presents an author video on a phase IIa randomised placebo-controlled trial of amlitelimab, an anti-OX40 ligand monoclonal antibody, in atopic dermatitis.
6:41 Upadacitinib vs Dupilumab for Itch in the Level Up Study
Christopher Bunick, MD, PhD, of Yale School of Medicine discusses itch results from the phase 3b/4 Level Up study (NCT05601882) comparing upadacitinib with dupilumab in moderate-to-severe atopic dermatitis, presented in 2026.